The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of April 2021, we identify the following current VC trends in the US Biotech sector:
- In 2021, overall Biotech funding in the USA has reached USD 12,828m so far
- Top 5 deals exceed USD 330m each, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
- Logos Capital (USA) leads the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and RA Capital Management (USA)
- Oncology dominates as the top indication
RESEARCH
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Licensing
Biotech Licensing Monitor – China-Upcoming-Recent licensing trends of European Biotech companies in China
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS & PRESS
IPO plans for magic-mushroom-holding: How good is the new project of German investor Christian Angermayer? | Handelsblatt 10.06.2021 – Quotes by FCF
On Thursday, June 10, the German newspaper “Handelsblatt” reported online and in its print version on the planned IPO of ATAI Life Sciences, a German company specializing in psychedelic drugs. Previously labeled as narcotic drugs,
FCF MedTech & Diagnostics Public Equity Monitor – May 2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF MedTech & Diagnostics Public Equity Monitor – May 2021”. The MedTech & Diagnostics Public Equity Monitor, part of FCF Life Sciences Research Series,
FCF Life Sciences Venture Capital Monitor – Europe 04/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2021”. The Monitor is a monthly published overview of venture capital trends in the European Life
FCF Life Sciences SPAC Monitor – 05/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences SPAC Monitor – 05/2021”. The Monitor is a quarterly published overview focusing on the performance of life sciences companies after the
FCF Life Sciences: Cool off for SPAC-Boom
Number of SPAC IPOs has stagnated since April Potential reason could be a Statement from U.S. Securities and Exchange Commission (SEC) 611 SPAC IPOs since May 2020 Munich, May 18, 2021 – The boom around
